Pancreatic cancer therapy and diagnosis

US10420757B2 · kind B2 · utility

Assignees

• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE
• The Royal Institution for the Advancement of Learning/McGill University · CA

Inventors

• Pouria Jandaghi · Montréal, CA
• Jorg Hoheisel · Wiesbaden, DE
• Yasser Riazalhosseini · Montréal, CA

Key dates

• Filing date: Apr 17, 2015
• Grant date: Sep 24, 2019
• Expiry date: Oct 18, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current disclosure relates to methods for treating pancreatic cancer or chronic pancreatitis in a subject comprising administering an antagonist of a dopamine receptor to the subject wherein the dopamine receptor is, in some specific cases dopamine receptor D2 (DRD2). The antagonist in some specific cases is an RNAi construct, an antibody, or a small molecule and in more specific cases pimozide or L-741,626. The disclosure also relates to diagnostic methods comprising the detection of the expression of DRD2 in pancreatic tissue and kits for doing the same.